ReviewCancer cell2024
Melanoma and microbiota: Current understanding and future directions.
Abstract readReview
In one paragraph
Review in Cancer cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.Journal for immunotherapy of cancer · 2025Trial
- The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers.Nature communications · 2024Trial
- Identification of human DP8α regulatory T cell sub-populations reactive to health-associated anti-inflammatory gut commensals.Gut microbes · 2026Article
- Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth.Cell reports. Medicine · 2026Article
- Article
- Enriched environment inhibits melanoma by reshaping gut microbiota and enriching Parabacteroides distasonis.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Microbiome in Gastrointestinal Tumors: Implications in Oncogenesis and Therapeutic Response : Microbiome in Gastrointestinal Tumors.Current oncology reports · 2026Review
- Meta-analytic microbiome target discovery for immune checkpoint inhibitor response in advanced melanoma.Communications medicine · 2026Article
- Exploring the Role of Gut Microbiota in Chronic Spontaneous Urticaria: Mechanisms and Potential Therapeutic Implications.Probiotics and antimicrobial proteins · 2026Review
- Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting.Annual review of immunology · 2026Review
- Microbiome, GvHD, and immune reconstitution in allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2026Review
- Antibiotic treatment indicates shorter survival in patients with immunotherapy for metastatic kidney cancer.Acta oncologica (Stockholm, Sweden) · 2026Article
- Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma.Nature medicine · 2026Article
- Exploring Fecal Microbiota Transplantation: Potential Benefits, Associated Risks, and Challenges in Cancer Treatment.Cancer reports (Hoboken, N.J.) · 2026Review
- The microbiome: regulating anti-tumor immunity.Frontiers in immunology · 2026Review
- Bacterial colonized melanoma skin models allow to study host-microbe interactionsFrontiers in microbiology · 2026Article
- Harnessing Next-Generation 3D Cancer Models to Elucidate Tumor-Microbiome Crosstalk.Advanced healthcare materials · 2026Review
- Local Delivery of Ginger ExtractCurrent drug delivery · 2026Article
- Role of Gut Microbiome in Oncogenesis and Oncotherapies.Cancers · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Bertrand RoutyUniversity of Montreal Research Center (CRCHUM), Montreal, QC H2X 0A9, Canada; Hematology-Oncology Division, Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 3E4, Canada.
Tanisha JacksonMelanoma Research Alliance, 730 15th Street NW, Washington, DC 20005, USA.
Laura MählmannSeerave Foundation, The Seerave Foundation, 35-37 New Street, St Helier, JE2 3RA Jersey, UK.
Christina K BaumgartnerOncology Discovery Research, AbbVie Inc, North Chicago, IL 60064, USA.
Martin BlaserCenter for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ 08854, USA.
Allyson ByrdDepartment of Cancer Immunology, Genentech, Inc., South San Francisco, CA 94080, USA.
Nathalie CorvaiaMaaT Pharma, 69007 Lyon, France.
Kasey CoutsDepartment of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Diwakar DavarDepartment of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Lisa DerosaGustave Roussy Cancer Center, ClinicoBiome, 94805 Villejuif, France; Université Paris Saclay, Faculty of Medicine, 94270 Kremlin Bicêtre, France; Inserm U1015, Equipe Labellisée par la Ligue Contre le Cancer, 94800 Villejuif, France.
Howard C HangDepartments of Immunology & Microbiology and Chemistry, Scripps Research, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
Geke HospersDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, 9713 GZ, Groningen, The Netherlands.
Morten IsaksenBio-Me, 0349 Oslo, Norway.
Guido KroemerCentre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, 75006 Paris, France; Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94905 Villejuif, France; Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France.
Florent MalardSorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
Kathy D McCoyDepartment of Physiology & Pharmacology, Snyder Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
Marlies MeiselDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA USA; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA USA.
Sumanta PalDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Ze'ev RonaiSanford Burnham Prebys Discovery Medical Research Institute, La Jolla, CA 92037, USA.
Eran SegalWeizmann Institute of Science, Computer Science and Applied Mathematics Department, 234th Herzel st., Rehovot 7610001, Israel.
Gregory D Sepich-PooreFeinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; Micronoma Inc., San Diego, CA 92121, USA.
Fyza ShaikhJohns Hopkins School of Medicine, Department of Oncology, Baltimore, MD 21287, USA.
Randy F SweisSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Giorgio TrinchieriCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Marcel van den BrinkDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Immunology, Sloan Kettering Institute, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA.
Rinse K WeersmaDepartment of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Katrine WhitesonDepartment of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA 92697, USA.
Liping ZhaoDepartment of Biochemistry and Microbiology, New Jersey Institute of Food, Nutrition and Health, Rutgers University, New Brunswick, NY 08901, USA.
Jennifer McQuadeDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: jmcquade@mdanderson.org.
Hassane ZarourUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA. Electronic address: zarourhm@upmc.edu.
Laurence ZitvogelGustave Roussy Cancer Center, ClinicoBiome, 94805 Villejuif, France; Université Paris Saclay, Faculty of Medicine, 94270 Kremlin Bicêtre, France; Inserm U1015, Equipe Labellisée par la Ligue Contre le Cancer, 94800 Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT), Gustave Roussy, 94805 Villejuif, France. Electronic address: laurence.zitvogel@orange.fr.
Funding
Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI BRIAN T BUCKLEY · 1988 to 2026
$47.4MRole of mouse microbiome in cancer and inflammationZIABC011153 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TRINCHIERI, GIORGIO · 2009 to 2025
$22.0MTranslation of commensal bacteria mechanism for immunotherapyR01CA245292 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI HANG, HOWARD C · 2020 to 2024
$2.7MTherapy with fecal microbiota transplantation and immune checkpoint blockade for solid tumorsU01CA268806 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HASSANE M ZAROUR · 2022 to 2026
$2.4MSystemic immunoregulatory consequences of bacterial translocation during health and diseaseR01DK130897 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MEISEL, MARLIES · 2021 to 2025
$2.2MRole of probiotic Lactobacillus reuteri in orchestrating systemic anti-tumor immunityR21CA259636 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MEISEL, MARLIES · 2022 to 2023
$377kNCI NIH HHS R01 CA245292NCI NIH HHS R21 CA259636NCI NIH HHS U01 CA268806NIDDK NIH HHS R01 DK130897NIEHS NIH HHS P30 ES005022
Abstract
Over the last decade, the composition of the gut microbiota has been found to correlate with the outcomes of cancer patients treated with immunotherapy. Accumulating evidence points to the various mechanisms by which intestinal bacteria act on distal tumors and how to harness this complex ecosystem to circumvent primary resistance to immune checkpoint inhibitors. Here, we review the state of the microbiota field in the context of melanoma, the recent breakthroughs in defining microbial modes of action, and how to modulate the microbiota to enhance response to cancer immunotherapy. The host-microbe interaction may be deciphered by the use of "omics" technologies, and will guide patient stratification and the development of microbiota-centered interventions. Efforts needed to advance the field and current gaps of knowledge are also discussed.
Indexed as
Gastrointestinal MicrobiomeMelanomaMicrobiotaNeoplasmsHost Microbial InteractionsHumansImmunotherapy
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.